Gasdermin C inhibitors are a class of chemical compounds that specifically target the gasdermin C (GSDMC) protein, which is a member of the gasdermin family. Gasdermins are known for their role in forming pores in the cell membrane, which can lead to pyroptosis, a type of programmed cell death. GSDMC, in particular, is involved in regulating membrane integrity and cell death pathways, and its inhibitors work by blocking the protein's ability to oligomerize and form pores. Structurally, gasdermin C inhibitors are diverse, encompassing a range of small molecules that interact with GSDMC through various binding sites. The molecular structure of these inhibitors often features aromatic rings, heterocyclic cores, or other moieties that enable strong binding affinity to GSDMC, effectively preventing the protein from transitioning into its active pore-forming state. This binding can either be direct, by interacting with the pore-forming domains, or indirect, by stabilizing GSDMC in its inactive conformation.
The study of gasdermin C inhibitors is primarily focused on understanding their mechanisms of action at the biochemical and molecular levels. Researchers investigate how these compounds modulate the protein's structural dynamics and its interaction with cellular membranes. By inhibiting GSDMC, these inhibitors can potentially control cellular processes like pyroptosis and membrane permeabilization, making them important tools for studying cell death pathways. The specificity of gasdermin C inhibitors is a key feature, as they are designed to selectively target GSDMC without affecting other gasdermin family members. The design and optimization of these inhibitors involve understanding the structural biology of GSDMC, including its active and inactive states, which are crucial for developing high-affinity and high-specificity compounds. Overall, gasdermin C inhibitors provide valuable insight into the role of GSDMC in cell biology and serve as essential chemical tools for probing the molecular pathways of cell death and membrane dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram can inhibit gasdermin-mediated pyroptosis by binding to gasdermins and preventing their pore-forming activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 inhibits NF-κB, a factor in inflammatory signaling, which might indirectly affect GSDMC activity. | ||||||
VX-765 | 273404-37-8 | sc-475845 sc-475845A sc-475845B | 5 mg 10 mg 50 mg | $228.00 $302.00 $968.00 | 1 | |
VX-765, a caspase-1 inhibitor, could indirectly modulate GSDMC activity, as caspase-1 is involved in pyroptosis. | ||||||
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
Anakinra, an IL-1 receptor antagonist, may indirectly influence GSDMC by modulating inflammatory responses. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide, a NF-κB inhibitor, could affect GSDMC activity through its role in inflammation. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 is another NF-κB inhibitor, potentially impacting pathways related to GSDMC. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide modulates TNF-alpha production, potentially influencing GSDMC-related pathways. | ||||||